Novo Nordisk raised its sales forecast for this year thanks to growing demand fo...
) raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline.
Sales of its new once-weekly injectable treatment, branded Ozempic, rose to 2.3 billion Danish crowns in the second quarter, which was higher than expected by analysts, sending shares in the world’s top diabetes drugmaker 1.4% higher in early trading on Friday. Novo, an early mover together with Eli Lilly in the sector, has a 46% share of the global GLP-1 market.
This includes four new late-stage clinical trials with semaglutide in people with type 2 diabetes and other complications, including cardiovascular disease, diabetic retinopathy and chronic kidney disease.While its new drug continued to shine, uncertainty remained in the United States where the Trump administration and other lawmakers have introduced several proposals aimed at lowering healthcare costs for U.S. consumers, some of which have already been scrapped.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Aussie, New Zealand dollars seen defying gravity, even as gravity wins out: Reuters pollAnalysts still maintain a remarkably sanguine outlook for the Australian and New...
Consulte Mais informação »
Lyft Raises 2019 Revenue Outlook and Sees Smaller Annual LossThe ride-hailing company raised its sales outlook for the year as more riders are using the service and as it appears to be curbing its heavy use of discounts.
Consulte Mais informação »
Asian central banks flag growth concerns with surprising rate cutsAsia central banks signaled major concerns on Wednesday about the outlook for ec...
Consulte Mais informação »
Prolonged uncertainty weighs on euro zone growth outlook: ECBProlonged uncertainty is dampening the euro zone's growth outlook, particul...
Consulte Mais informação »
The New York Times “Deadline” Sale Revisited: Happy Fruit Meets A Twitter MobPity the poor promotional gurus at the New York Times Company. Just as they were wrapping themselves around a kinder, gentler digital subscription pitch — keyed to the notion that reading The…
Consulte Mais informação »
FDA backs Gilead's HIV prevention drug for certain populationFDA advisory panel on Wednesday votes in favor of Gilead's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.
Consulte Mais informação »